Not Tagged
Not Tagged
['dlbcl', 'car-t', 'great work']
#asco22 great work on cost effectiveness of cd19 car-t therapy vs asct for high-risk dlbcl in first relapse. with current pricing , not cost effective. solution : so easy drop down the price 
Assistant professor @UAMSMyeloma. Alumni heme/onc @bcmhouston, clinical research/biostat @UMich.Focus on plasma cell disorders & health disparities. No COI